Paclitaxel (CAS 33069-62-4) in 2026: Efficacy and Sourcing
Content
What Defines Paclitaxel in 2026?
Originally isolated from the Pacific yew (*Taxus brevifolia*), Paclitaxel is a tetracyclic diterpenoid known for its unique mitotic inhibitory properties. Unlike many chemotherapy agents that prevent microtubule assembly, Paclitaxel stabilizes microtubules, effectively "locking" the cell in mitosis and triggering apoptosis.
The 2026 Sourcing Shift: The industry has moved entirely away from wild bark harvesting. Modern B2B supply chains, including ours at Shaanxi Sunrise, rely on Plant Cell Culture Technology (PCCT) and 10-DAB III semi-synthesis to ensure 99% purity without ecological impact.
Clinical Efficacy Across Malignancies
The role of Paclitaxel in 2026 continues to expand through combination therapy. It remains the first-line standard for:
Breast & Ovarian Cancer: Often used as the backbone in adjuvant and neoadjuvant settings.
Non-Small Cell Lung Cancer (NSCLC): Particularly when paired with platinum-based agents or immunotherapy.
Advanced Solid Tumors: Showing renewed potential in refractory cases through Albumin-bound (nab) delivery formats.
Next-Gen Delivery: Overcoming Solubility and Resistance
A major focus in 2026 is the elimination of solvent-related toxicities (like those from Cremophor EL). Nanocarrier technology and liposomal formulations are significantly improving the bioavailability of Paclitaxel, allowing for higher tumor concentration and lower systemic side effects.
Furthermore, managing drug resistance is being addressed via "Immune-Priming." Paclitaxel is increasingly recognized for its ability to modulate the tumor microenvironment, making it a perfect partner for PD-1/PD-L1 inhibitors in synergistic protocols.
| Technical Parameter | 2026 Shaanxi Sunrise Standard |
|---|---|
| Common Name | Paclitaxel (API Grade) |
| CAS Registry Number | 33069-62-4 |
| Purity (HPLC) | ≥ 99.0% / ≥ 99.5% (Custom Grade) |
| Appearance | White to off-white crystalline powder |
| Extraction Route | Semi-synthetic (from 10-DAB III) / PCCT |
| Compliance | GMP, ISO 9001:2015, DMF Registered |
Expert FAQ: Procurement & Safety
1. How should Paclitaxel be administered to minimize allergic reactions?
Clinical protocols in 2026 still emphasize pre-medication with corticosteroids and antihistamines. However, the shift toward nab-Paclitaxel (albumin-bound) has significantly reduced the incidence of severe hypersensitivity seen with older formulations.
2. What are the common side effects and their management?
Bone marrow suppression and peripheral neurotoxicity remain the primary concerns. Current supportive care includes G-CSF for hematological support and precision-dose adjustments based on patient-specific biomarker responses.
3. Why is Shaanxi Sunrise's Paclitaxel API preferred by global manufacturers?
With over a decade of experience, we control the entire vertical—from 10-DAB III precursors to the final high-purity API. Our ISO 9001:2015 facility ensures batch-to-batch consistency that meets the stringent requirements of pharmaceutical plants in Europe and North America.
Academic References:
1. Wani, M. C., et al. (1971). Isolation and Structure of Taxol. *J. Am. Chem. Soc.*
2. Rowinsky, E. K., & Donehower, R. C. (1995). Paclitaxel (Taxol). *NEJM*.
3. Shaanxi Sunrise Internal Quality Control (2026): Advances in PCCT-based Paclitaxel Production.
1. Wani, M. C., et al. (1971). Isolation and Structure of Taxol. *J. Am. Chem. Soc.*
2. Rowinsky, E. K., & Donehower, R. C. (1995). Paclitaxel (Taxol). *NEJM*.
3. Shaanxi Sunrise Internal Quality Control (2026): Advances in PCCT-based Paclitaxel Production.